Clinical research company Shire's velaglucerase alfa for injection (VPRIV) therapy has been proved to improve the health of patients with Goucher-related bone disease.
It was found that VPRIV boosts the condition by causing a sustained increase in bone mineral density (BMD), which can be used to assess the effect of the illness on patients' bones.
Professor Ari Zimran from Shaare Zedek Medical Centre at Hebrew University and Hadassah Medical School in Israel, said: "These study results show that VPRIV is effective in treating selected markers of Gaucher-related bone disease, allowing these patients to achieve an important therapeutic goal quickly."
The research discovered that there is substantial improvement in lumbar spine BMD in patients with the disease after nine months of treatment.
Last month, Shire released data on its study into lisdexamfetamine dimesylate, which found that the drug can maintain efficacy in children and adults with ADHD.
The overall nature of treatment-emergent adverse events was also consistent with previous research.